ArticleEuropean journal of pediatrics2025
Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020-2023 in Europe.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiological and Clinical Characteristics of Bronchiolitis and the Impact of RSV Infection: A Five-Year Study in a Tertiary Pediatric Center in Central Romania.Pediatric reports · 2026Article
- Article
- Impact of RSV hospitalization on healthcare costs, caregivers' productivity loss, and quality of life in children ≤ 2 years old in five European countries.European journal of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the newly approved RSV preventive strategies enabling universal protection of infants, it is crucial to gain a comprehensive understanding of RSV hospitalization incidence, prior to the introduction of these strategies in order to facilitate an assessment of their impact. Children ≤ 2 years hospitalized with laboratory-confirmed RSV infection between 2020-2023 in France, Germany, Spain, Italy, and United Kingdom were included and compared with the 2018-2019 season. The population-based incidence was calculated as number of RSV hospitalizations divided by market share-adjusted number of children in the catchment area. Across participating countries, we observed a decrease in RSV hospitalization incidence during the 2020-2021 season due to the COVID-19 pandemic, dropping to 5.9/1000 child-years (95%CI 5.4-6.3) compared with 11.3/1000 child-years (95%CI 10.6-11.9) in 2018-2019. This decline was followed by a rebound in incidence, with rates reaching 13.8/1000 child-years (95%CI 13.0-14.5) in 2021-2022 and 18.8/1000 child-years (95%CI 18.0-19.7) in 2022-2023. Distinct patterns of RSV resurgence were observed across countries. During the 2020-2021 season, there was an increase in PICU admissions (29.5% vs 20.0% pre-pandemic, p < 0.001), despite a lower total number of RSV admissions (610 vs 1,238) compared to the 2018-2019 season.
conclusionsThe population-based incidence of RSV hospitalization in children ≤ 2 years is substantial. Considerable variation in incidence was observed between 2020 and 2023, with an initial decline during the COVID-19 pandemic followed by a rebound in the subsequent seasons. Our study underscores the importance of RSV surveillance and flexibility in RSV preventive strategies. WHAT IS KNOWN: • RSV is a major cause of hospitalization in young children under 5 years of age worldwide. • RSV seasonality was disrupted during the COVID-19 pandemic. WHAT IS NEW: • Distinct patterns of RSV resurgence were observed across five European countries during the COVID-19 pandemic, with an initial decline in incidence of RSV associated hospitalizations in children ≤ 2 years, followed by a rebound in the subsequent seasons, reaching 18.8 per 1,000 child-years (95% CI: 18.0 - 19.7) in 2022-2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.